Press release
Myotonic Dystrophy Drug Market Size | COVID-19 Impact Analysis | Forecast to 2028
The global myotonic dystrophy drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Myotonic dystrophy is a muscular dystrophy caused by a long-term genetic mutation. It is the most common type of muscular dystrophy in adulthood, affecting roughly one out of every 8,000 people. Muscle atrophy and weakness worsen over time as a symptom. Muscles contract frequently and take a long time to relax. Some people have a relatively mild type, while others have a severe one that affects them from birth. This is owing to the condition's molecular foundation, which is caused by a dynamic mutation called a triplet repeat expansion, which occurs when three base pairs of DNA are present in varied copies numbers.To Request a Sample of our Report on Myotonic Dystrophy Drug Market: https://www.omrglobal.com/request-sample/myotonic-dystrophy-drug-market
The primary factor propelling the growth of global myotonic dystrophy market is the introduction of novel disease therapeutics and increased R&D activities. For instance, in November 2021, Locanabio, Inc., a genetic pharmaceuticals business focused on developing therapies for patients with severe neuromuscular, neurodegenerative, and retinal illnesses, announced new preclinical data from its myotonic dystrophy type 1 (DM1) program. Locanabio scientists used their CORRECTx platform to show a dose-dependent reduction in toxic CUG foci in both DM1 patient muscle cells and a preclinical mouse model of DM1, which resulted in an alternative RNA splicing correction and a statistically significant reduction in myotonia, or muscle weakness. Further, in April 2020, Scientists from the University's Schools of Life Sciences and Chemistry have discovered that inhibiting a molecule in patients' cells called CDK12 can potentially develop a therapy to alleviate some of the symptoms and support treat this incurable condition.
Some major key players in the market include Isis Pharmaceuticals, Inc., and Lupin Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in October 2021, AOC 1001 has been granted Fast Track designation by the Food and Drug Administration (FDA) for the treatment of myotonic dystrophy type 1 (DM1). AOC 1001 is a monoclonal antibody that binds to transferrin receptor 1 and is coupled to a short interfering RNA that targets DMPK mRNA. AOC 1001 is expected to address the fundamental cause of DM1 by lowering DMPK mRNA levels in skeletal, cardiac, and smooth muscle. Data from preclinical tests back up the designation, showing that AOC 1001 successfully transported the small interfering RNA to muscle cells, resulting in dose-dependent decreases in DMPK mRNA.
Market Coverage
· The market number available for - 2021-2028
· Base year- 2021
· Forecast period- 2022-2028
Segment Covered-
· By Type
· By Application
Regions Covered-
· North America
· Europe
· Asia-Pacific
· Rest of the World
Competitive Landscape- Isis Pharmaceuticals, Inc., and Lupin Ltd., among others.
(Get 15% Discount on Buying this Report)
A full Report of Myotonic Dystrophy Drug MarketReceiver is Available @ https://www.omrglobal.com/industry-reports/myotonic-dystrophy-drug-market
Global Myotonic Dystrophy Drug Market Report by Segment
By Type
· Myotonic Dystrophy Type 1 (DM1)
· Myotonic Dystrophy Type 2 (DM2)
By Application
· Hospital
· Clinic
· Others
Global Myotonic Dystrophy Drug Market Report by Region
North America
· United States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest of Europe
Asia-Pacific
· India
· China
· Japan
· South Korea
· Rest of APAC
Rest of the World
· Latin America
· Middle East & Africa
Reasons to buy from us -
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myotonic Dystrophy Drug Market Size | COVID-19 Impact Analysis | Forecast to 2028 here
News-ID: 2584519 • Views: …
More Releases from Orion Market Research

Infrastructure as Code (IaC) Service Market Size Analysis, Competitive Insights, …
Infrastructure as Code (IaC) Service Market was valued at approximately USD 0.932 billion, and it's projected to expand to around USD 7.509 billion by 2033, achieving a robust CAGR of 23.2% from 2024 to 2033.
Infrastructure as Code (IaC) Service Market Overview
The Infrastructure as Code (IaC) Service Market is experiencing remarkable expansion, fueled by the escalating need for scalable, automated infrastructure deployment across cloud and enterprise environments. In 2023, the market…

Ultra High-Performance Liquid Chromatography (UHPLC) Columns Market : A Guide to …
Ultra High‐Performance Liquid Chromatography (UHPLC) Columns Market is estimated to be valued at USD 2.5 billion, and is projected to grow to approximately USD 4.8 billion by 2033, representing a compound annual growth rate (CAGR) of about 7.8% from 2024 to 2033.
Ultra High-Performance Liquid Chromatography (UHPLC) Columns Market Overview
The UHPLC columns market is on a strong growth trajectory, fueled by increasing demand for rapid, high-resolution analytical techniques across pharmaceuticals, biotechnology,…

Property Management Service Market Rising Demand and Growth Forecast Through 203 …
Property Management Service Market was valued at approximately USD 17.3 billion. It is anticipated to reach around USD 32.0 billion by 2033, growing at a compound annual growth rate (CAGR) of 7.3% from 2024 to 2033.
Property Management Service Market Overview
The Property Management Service Market is witnessing steady growth due to increasing urbanization, rising investments in real estate, and a growing demand for outsourced property management solutions. Property owners are increasingly…

5G Chipset Market Set to Witness Significant Growth by 2033 | Apple Inc., HiSili …
The global 5G chipset market was valued at USD 33.75 billion in 2024 and is projected to reach USD 502.66 billion by 2033, growing at a compound annual growth rate (CAGR) of 35% from 2025 to 2033.
5G Chipset Market Overview
The 5G chipset market is experiencing rapid growth, driven by the global rollout of 5G networks and the increasing demand for high-speed, low-latency connectivity across various applications, including smartphones, IoT…
More Releases for Myotonic
UK Myotonic Dystrophy Drug Market Segments |Latest Innovations & Demands
"Detailed Study of Myotonic Dystrophy Drug Market (2024-2032)
New Analysis Of Myotonic Dystrophy Drug Market overview, spend analysis, imports, segmentation, key players and opportunity analysis 2024-2032. The study also includes an in-depth competitive analysis of the key market players, along with their company profiles, key observations related to product and business offerings, recent developments, and key market strategies.
It also provides a snapshot of the country's economy and Industry outlook. It provides…
Myotonic Dystrophy Medication Market Business Growth, Trends, and Challenges by …
A New report from the WGR, titled Myotonic Dystrophy Medication Market Report 2024 Market Size, Trends, and Global Forecast 2024-2032, offers a thorough analysis of the market's changing trends, investment opportunities, and competitive landscape. By the end of 2032, the Myotonic Dystrophy Medication market trends will be valued at USD 1.1, per a WGR analysis. Furthermore, the report projects that the Myotonic Dystrophy Medication market trends will grow at a…
Myotonic Dystrophy Market Size, Epidemiology, Analysis & Trends 2023-2033
Myotonic Dystrophy Market Report Overview:
Report Attribute Details
Base Year 2022
Forecast Years …
Myotonic Dystrophy Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 …
DelveInsight's, "Myotonic Dystrophy Pipeline Insight, 2023," report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Myotonic Dystrophy pipeline landscape. It covers the Myotonic Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myotonic Dystrophy Pipeline…
Emerging Trends in the 2022-2029 Myotonic Dystrophy Medication Market
Global Industrial aspects of Myotonic Dystrophy Medication Sales Market 2023-2029: The global Myotonic Dystrophy Medication Market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Myotonic Dystrophy Medication is estimated to increase from $ million in…
Emerging Trends in the 2022-2029 Myotonic Dystrophy Medication Market
Global Industrial aspects of Myotonic Dystrophy Medication Sales Market 2023-2029: The global Myotonic Dystrophy Medication Market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Myotonic Dystrophy Medication is estimated to increase from $ million in…